Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 2/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 8/20 | 0.34 |
| ▸ | LCK | P06239 | 3/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | AURKA | O14965 | 2/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14118683 | 0.91 | AKT1 (0.39) | FAPPTPN11LCKTNK2KDR | |
| SCHEMBL1902096 | 0.89 | PTPN11 (0.39) | PTPN11LCKTNK2KDRJAK3 | |
| SCHEMBL1905949 | 0.86 | AURKA (0.46) | PTPN11LCKTNK2AURKA | |
| SCHEMBL1904033 | 0.86 | AURKA (0.37) | PTPN11TNK2KDRAURKAPDE2A | |
| SCHEMBL12095251 | 0.86 | PTPN11 (0.38) | PTPN11 | |
| SCHEMBL1904499 | 0.85 | AURKA (0.42) | PTPN11LCKTNK2AURKA | |
| SCHEMBL14120192 | 0.84 | CHEK1 (0.37) | LCKTNK2KDRJAK3AURKA | |
| SCHEMBL1902450 | 0.82 | ALDH1A1 (0.35) | TNK2KDRAURKAPDE2AKDM4E | |
| SCHEMBL1904734 | 0.82 | ALDH1A1 (0.36) | TNK2KDRAURKAPDE2A | |
| SCHEMBL14118880 | 0.81 | SCN9A (0.36) | LCKTNK2AURKAPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | FAP 2798/4885PTPN11 1410/4885LCK 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.